HomeMarket News89bio Nabs Regulatory Nod for Phase 3 NASH Trials

89bio Nabs Regulatory Nod for Phase 3 NASH Trials

Actionable Trade Ideas

always free

Human Internal Digestive Organ Liver Anatomy

magicmine/iStock via Getty Images

Regulators in the U.S. and EU have given 89bio (NASDAQ:ETNB) the green light for the Phase 3 trials of pegozafermin, a potential treatment for nonalcoholic steatohepatitis (NASH), announced the company on Monday.

Following an end-of-phase 2 meeting with the U.S. Food and Drug Administration (FDA), the company revealed that both U.S. and EU officials were aligned with their Phase 3 plans for pegozafermin, a synthetic version of fibroblast growth factor 21 (FGF21) used in the treatment of NASH.

89bio (ETNB) will move forward with the ENLIGHTEN-Cirrhosis trial for NASH patients with compensated cirrhosis (F4) and the ENLIGHTEN-Fibrosis trial for NASH patients with fibrosis stage F2-F3.

The company intends to commence the ENLIGHTEN-Cirrhosis trial in Q1 and the ENLIGHTEN-Fibrosis trial in Q2 of 2024. Additionally, 89bio (ETNB) plans to enroll a significant number of NASH patients who are currently on GLP-1 drugs such as Eli Lilly’s (LLY) Zepbound and Novo Nordisk’s (NVO) Wegovy across both studies, aiming to evaluate the benefits of adding pegozafermin to GLP-1 therapy.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.